SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors are keenly focused on recent technical breakouts and the potential for S&P 500 inclusion, with many anticipating a pre-earnings rally. The community is actively debating the impact of recent capital raises and the upcoming stablecoin launch, alongside performance targets for the CEO. Bullish sentiment is countered by concerns over past share dilution and price volatility, though the broader fintech sector's momentum adds to the conversation.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending sharply upward following positive Phase 3 clinical trial results for its oral TYK2 inhibitor, envudeucitinib, in moderate-to-severe plaque psoriasis, showcasing exceptional skin clearance rates. The community is actively debating if these strong efficacy outcomes justify the significant market reaction, with some anticipating a classic biotech pump-and-dump while others view it as a high-potential long-term opportunity in the competitive immunology space.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending due to its strategic collaboration with OpenAI, enhancing its Athena AI marketing platform with advanced conversational intelligence, an announcement made at CES 2026. This news has ignited strong community discussion, with many anticipating a significant short squeeze given the stock's high short interest and perceived undervaluation. Investors are actively highlighting Zeta's position as a burgeoning leader in the AI-driven MarTech sector and its strengthening fundamentals.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to overwhelming short squeeze speculation, fueled by exorbitant borrow fees, limited share availability, and its inclusion on the Reg SHO list. The community is actively celebrating the stock sustaining above the critical $5 mark, which is seen as a gateway for institutional investment, and expressing high conviction in the groundbreaking potential of its GPS immunotherapy for AML. This confluence of factors, including promising clinical trial progress suggesting significantly extended patient survival, is driving intense discussion around a potential multi-billion dollar buyout and a significant re-rating of the company's value.

Memecoin on Injective taken over by the community.

Nonja

NONJA is trending as a top meme coin on the Injective blockchain, driven by its strong community actively discussing its leveraged performance against INJ and resilience during market downturns. The community highlights NONJA's organic growth, high burned liquidity, and successful NFT collections, positioning it for significant gains as Injective's ecosystem benefits from its robust fundamentals and upcoming ETF considerations.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing a significant surge in trading volume, driving strong bullish sentiment and community discussions predicting a notable price ascent. The conversation highlights its foundational technology in IoT and decentralized data, bolstered by Japanese regulatory compliance and anticipated 2026 ecosystem developments, with many viewing it as a long-term investment in a real technology project.

Aeva Technologies, Inc. develops sensing paradigm for autonomous vehicles and robotics. The firm offers drones, robotics, vehicle technology, and virtual and augmented reality products. The company was founded by Soroush Salehian Dardashti and Mina Rezk in 2017 and is headquartered in Mountain View, CA.

Aeva Technologies Inc

Aeva Technologies is generating significant buzz following announcements at CES 2026, most notably the integration of its 4D LiDAR as a reference sensor within the NVIDIA DRIVE Hyperion Platform ecosystem. The community is highly enthusiastic about this validation and Aeva's new Omni sensor for Physical AI applications, anticipating substantial stock appreciation driven by its low float and perceived technological leadership.

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in Chicago, IL.

Bright Minds Biosciences Inc

Bright Minds Biosciences is currently trending following positive Phase 2 clinical data for BMB-101, showing strong efficacy and a clean safety profile in treating drug-resistant epilepsy. This promising update has ignited intense community discussion, with many drawing parallels to prior explosive biotech surges and debating the potential for a significant short squeeze, while others express surprise at the market's reaction despite the scientific advancements.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to its pivotal role in the U.S. Department of Energy's Advanced Reactor Pilot Program, targeting an Integral Molten Salt Reactor pilot by July 2026, complemented by a recent Westinghouse contract for advanced nuclear fuel. The community is actively debating its significant undervaluation compared to peers like OKLO, highlighting its LEU fuel advantage and potential to power future AI data centers and industrial heat. Despite recent post-SPAC volatility, many investors view current levels as a key accumulation opportunity for this government-backed nuclear innovator.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as investors eagerly await a U.S. Department of Energy announcement on surplus plutonium fuel allocation, seen as critical for its advanced reactor development and the broader 'American Energy Dominance' push. The community is actively discussing the potential for 'fast-track' licensing for Small Modular Reactors and a significant short squeeze, driven by expectations that Oklo is poised to power the growing energy demands of AI data centers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation.</li><li>The company expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.</li><li>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities.</li></ul>Ondas Holdings Inc. (ONDS) became one of the top trending tickers on Stocktwits and the company’s shares rose 4% in early trading on Tuesday following the announcement that it has entered into a definitive agreement to acquire Sentry CS, an Israel-based company in Cyber-over-RF (CoRF) and Protocol-Manipulation counter-Unmanned Aerial Systems (UAS) technology."The addition of Sentrycs will strengthen our leadership in counter-UAS and solidify Ondas' position as a full-spectrum provider of autonomous defense solutions," said Eric Brock, Chairman and CEO of Ondas Holdings.&nbsp;Ondas expects the transaction to close in November 2025. The terms of the deal were not disclosed.Retail sentiment on Ondas jumped to ‘bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Sentry CS’ Technology</h2>Ondas said that Sentry CS has seen rapid growth, with combat-proven deployments across 25 countries, and has achieved fully operational threat mitigation."Passive RF detection and tracking are essential to modern layered defense, and Sentrycs brings a proven technology platform already deployed across sensitive airspace, critical infrastructure, and border environments,” Brock said.Brock added that by integrating Sentry CS with Ondas’ Iron Drone Raider system, the company expects to deliver a unified detect-to-defeat solution that addresses the rapidly evolving threat landscape for its defense and homeland security customers worldwide.<h2 class="st-heading-2">Ondas’ Recent Slew Of Acquisitions</h2>Last week, Ondas announced a definitive agreement to acquire a controlling interest in 4M Defense, an Israeli smart demining company specializing in advanced demining capabilities, including robotic systems with terrestrial and subsurface AI-powered intelligence technologies.Ondas had noted that 4M Defense will expand Ondas Autonomous Systems’ addressable market into the large global landmine and UXOs clearance and subsurface intelligence platforms market.The company had also announced the acquisition of a controlling interest in Insight Intelligent Sensors, an Israeli developer of AI-driven electro-optical sensing systems.<a href="https://stocktwits.com/symbol/ONDS">Shares of Ondas</a> have gained over 771% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dennys-620-million-deal-oppenheimer-says-not-expecting-competitive-bidding-process/cL28guSR36a">Denny's $620 Million Deal: Oppenheimer Says Not Expecting ‘Competitive Bidding Process’</a>

In this photo illustration, a person holds a smartphone displaying the logo of Ondas Holdings Inc. 

ONDS Stock Rises Following Acquisition Of Israel-Based Sentry CS

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.

Equity

Ondas expects the transaction to close in November 2025, and the terms of the deal have not been disclosed.


Time to fade momentum trade, Jefferies says

Investing.com -- The momentum factor weakened in December, but more downside can be expected in the first quarter, according to a Jefferies strategist.

Shares of Aquestive Therapeutics, Inc. (<a class="mention" data-mention="$AQST" data-symbol-id="AQST" href="https://stocktwits.com/symbol/AQST" target="_blank">$AQST</a>) traded flat early on Thursday, paring pre-market gains, amid a surge in retail chatter that pushed the stock into the top 10 trending tickers on Stocktwits.&nbsp;The company reported positive topline results from its Oral Allergy Syndrome (OAS) challenge study for its Anaphylm Sublingual Film.&nbsp;This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. Food and Drug Administration (FDA).Both the primary and secondary endpoints of the study were successfully met, with no significant differences observed between Anaphylm’s pharmacokinetics (PK) in subjects with and without allergen exposure.&nbsp;The Tmax, or time to maximum plasma concentration, remained at 12 minutes in both groups, while the Cmax, or maximum plasma concentration, was consistent between them.&nbsp;The drug was also found to be safe and well-tolerated, with all adverse events reported as mild or moderate, resolving without medical intervention.On Stocktwits, retail sentiment for AQST surged into the ‘extremely bullish’ zone as of 9:30 am ET, accompanied by a sharp increase in message volume.<stembedurl>https://stocktwits.com/Outrageous/message/589944616</stembedurl><stembedurl>https://stocktwits.com/BioEmerging/message/589945926</stembedurl>A little over a week ago, H.C. Wainwright raised its price target on Aquestive Therapeutics to $10 from $9, maintaining a ‘Buy’ rating.&nbsp;The analyst cited the company’s virtual investor day, which provided insights into its technology platform, product development, and long-term strategy.Last month, Aquestive highlighted its Anaphylm Sublingual Film and AQST-108 Topical Gel during the event, both emerging from the company’s Adrenaverse epinephrine prodrug platform.&nbsp;CEO Daniel Barber expressed optimism about the company’s pipeline, mentioning that they had submitted a pre-NDA meeting request to the FDA for Anaphylm and were on track to report topline data from the OAS study.Looking ahead, the company expects to hold a pre-Investigational New Drug (IND) meeting with the FDA in Q1 2025 and plans to begin a Phase 2 study for AQST-108, targeting alopecia areata, in the second half of 2025, pending FDA alignment.Aquestive’s stock has gained over 160% year-to-date.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-jumps-after-q3-earnings-beat/cJ218ORR7f">Viking Therapeutics Stock Jumps After Q3 Earnings Beat: Retail Stays Cheerful</a>

Aquestive Therapeutics Pushes Retail Sentiment Into ‘Extremely Bullish’ Zone On OAS Drug Trial Success

This study marks the final supportive adult trial in the Anaphylm development program ahead of discussions with the U.S. FDA.

Invesco Capital Management LLC - Invesco Dorsey Wright SmallCap Momentum ETF

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$96.87
Prev Close	$96.24
Open	$96.25
Dividend Yield	N/A
50-Day Moving Average	$95.41
Beta	N/A
Avg. Volume	19,546.41
PE Ratio	N/A

52-Week High	$101.71
52-Week Low	$66.94
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DWAS
Invesco Dorsey Wright SmallCap Momentum ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DWAS News

DWASInvesco Dorsey Wright SmallCap Momentum ETF